A high-content imaging workflow to screen for molecules that reduce cellular uptake of α-synuclein preformed fibrils

作者：Wolfgang E Reintsch, Andrea I. Krahn, Chanshuai Han, Emmanuelle Nguyen, Carol X-Q Chen, Wen Luo, Irina Shlaifer, Tom Pfeifer, Edward A. Fon, Thomas M. Durcan · 发表于：bioRxiv (Cold Spring Harbor Laboratory) · 年份：2025 · DOI：10.64898/2025.12.22.695981 · 被引用次数：1 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Neurological disorders and treatments、Nerve injury and regeneration

Abstract A classical pathological hallmark of many neurodegenerative diseases is the formation of protein-rich aggregates and inclusions. In Parkinson’s disease (PD), α-synuclein (α-syn) constitutes a major protein component of pathological inclusions, termed Lewy bodies. These α-syn aggregates are hypothesized to spread throughout the nervous system by cell-to-cell transmission acting as templates to amplify aggregate formation. In vitro generated α-syn aggregates, commonly called preformed fibrils (PFFs), have been used to investigate a number of aspects related to α-syn mediated pathology across different model systems. Here we describe a semi-automated assay to screen for small molecules that interfere with the cellular uptake and accumulation of PFFs. The assay uses dopaminergic progenitor cells (DPCs), derived from human induced pluripotent stem cells (hiPSCs). In an initial screen, we tested 1520 small molecules and identified several molecules that strongly reduce intracellular PFF load in DPCs. From these hits, candidate compounds were validated in dopaminergic neurons (DNs) to demonstrate the utility of the assay. This assay provides a robust, scalable and adaptable tool to screen for molecules that affect PFF uptake in hiPSC-derived cell models. Within the scope of this screen, it led to the identification of a set of compounds with diverse annotated targets that effectively reduce the uptake of synuclein aggregates in DPCs and DNs.